| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Legal Officer | See Remarks | Former Executive Officer +2 more
2 companies
Berkman Charles S is a Chief Legal Officer at OABI, with reported holdings spanning 2 companies. Recent filings cover 0 purchases and 24 sales.
Our model assigns Berkman Charles S a strong insider score of 82/100, based on 10 past trades. Over a 12-month horizon, 100.0% of those trades were profitable, with an average 12-month return of +47.9%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 7, 2026 | OABI Omniab, Inc. | Chief Legal Officer | Sale+OE | 7,157 | $1.49 | $10,663.93 | -1.8% | +59.6% | - | |
| Feb 18, 2026 | OABI Omniab, Inc. | Chief Legal Officer | Sale+OE | 9,673 | $1.71 | $16,540.83 | -2.4% | +38.6% | - | |
| Feb 17, 2026 | OABI Omniab, Inc. | Chief Legal Officer | Sale+OE | 6,990 | $1.70 | $11,883.00 | -1.8% | +33.9% | - | |
| Dec 8, 2025 | OABI Omniab, Inc. | Chief Legal Officer | Sale+OE | 8,044 | $1.96 | $15,766.24 | -2.1% | -2.0% | - | |
| Apr 7, 2025 | OABI Omniab, Inc. | Chief Legal Officer | Sale+OE | 7,206 | $2.00 | $14,412.00 | -1.9% | -10.5% | -27.8% | |
| Feb 19, 2025 | OABI Omniab, Inc. | Chief Legal Officer | Sale+OE | 15,470 | $3.68 | $56,857.05 | -4.2% | -58.0% | -53.4% | |
| Jan 21, 2025 | OABI Omniab, Inc. | Chief Legal Officer | Sell | 25,489 | $3.24 | $82,584.36 | -6.9% | -43.2% | -37.6% | |
| Dec 9, 2024 | OABI Omniab, Inc. | Chief Legal Officer | Sale+OE | 8,022 | $4.13 | $33,130.86 | -2.4% | -20.0% | -51.0% | |
| Apr 8, 2024 | OABI Omniab, Inc. | Chief Legal Officer | Sale+OE | 6,954 | $5.27 | $36,647.58 | -2.3% | -26.2% | -64.1% | |
| Feb 4, 2021 | LGND Ligand Pharmaceuticals Inc | SVP, Gen. Counsel &Secretary | Sell | 18,097 | $178.50 | $3,230,376.03 | -38.5% | - | - |